NCT06747130View on ClinicalTrials.gov

Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
DengueMontelukastTransaminases
Interventions
DRUG

Montelukast

A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter

DRUG

Montelukast Placebo

A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter

Trial Locations (1)

10400

RECRUITING

Phramongkutklao Hospital, Bangkok

All Listed Sponsors
lead

Phramongkutklao College of Medicine and Hospital

OTHER